FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

February 19, 2019 – The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection. This is the first anti–PD-1 therapy evaluated in the adjuvant setting across patients with stage IIIA, stage IIIB, and stage IIIC melanoma. The approval is based on findings from the pivotal phase III EORTC 1325/KEYNOTE-054 trial, in which adjuvant pembrolizumab … (leggi tutto)